- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Cedars-Sinai Cancer | Strategic Alliance Partners
Cedars-Sinai Cancer in Los Angeles serves one of the most diverse regions globally. Ranked No. 7 for cancer by U.S. News & World Report 2020-2021, the center’s clinicians are committed to providing compassionate, state-of-the-art care, while its scientists are carrying out the latest translational research and groundbreaking advances. The cancer enterprise includes the Samuel Oschin Comprehensive Cancer Institute, The Angeles Clinic and Research Institute, Tower Hematology Oncology Medical Group, Torrance Memorial Hunt Cancer Center and Cedars-Sinai Tarzana.
Latest from Cedars-Sinai Cancer
ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer
October 08, 2024
Article
Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.
Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests
October 05, 2024
Article
Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.
Dr Yuan on the Evolution of Radiation Therapy Approaches in Breast Cancer
September 17, 2024
Video
Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.
Dr Yuan on the Investigation of Adjuvant CDK4/6 Inhibition in Breast Cancer
September 16, 2024
Video
Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.
Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC
July 25, 2024
Video
Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.
Final Thoughts on CSPC
July 17, 2024
Video
Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.
Patient Case 2: Metastatic CSPC
July 17, 2024
Video
Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case.
Dr Gong on the Importance of Molecular Profiling in mCRPC
July 15, 2024
Video
Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.
Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC
June 28, 2024
Video
Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.
Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC
June 26, 2024
Video
Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.
Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs
June 20, 2024
Podcast
Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.
Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC
May 04, 2024
Article
Enzalutamide alone and with leuprolide led to greater rates of undetectable PSA levels vs leuprolide alone in castration-sensitive prostate cancer.
Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices
April 15, 2024
Podcast
Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.
Dr Nguyen on the Role of Concurrent Chemotherapy With TMT in MIBC
February 21, 2024
Video
Anthony T. Nguyen, MD, PhD, discusses the role of concurrent chemotherapy with trimodal therapy in patients with muscle-invasive bladder cancer.
Dr Gong on the EMBARK Trial Investigating Enzalutamide in nmCSPC
February 20, 2024
Video
Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.
Dr Nguyen on Trimodal Therapy in MIBC
February 15, 2024
Video
Anthony T. Nguyen, MD, PhD, discusses the methodology of trimodal therapy in patients with muscle-invasive bladder cancer.
Dr Gong on the Current Treatment Armamentarium in mHSPC
February 07, 2024
Video
Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.
Dr. Gong on Addressing Unmet Needs Through Ongoing Research in Prostate Cancer
January 29, 2024
Video
Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.
Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC
December 08, 2023
Video
Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.
Dr Hitchins on Investigating Constitutional MLH1 Methylation in CRC and Endometrial Cancers
August 22, 2023
Video
Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.